PBAC's latest decision on Nivolumab and ipilimumab: Noted (2024). Considered for First-line treatment of patients with unresectable malignant pleural mesothelioma.
PBAC outcome
Noted
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2018
Submissions
3
2018 → 2024
Eligible population
Patients with unresectable malignant pleural mesothelioma eligible for first-line treatment (ECOG 0-1 performance status).
Therapy area
Oncology
Line of therapy
First-line
Evidence base
Cost-minimisation
Key trials
CheckMate 743
Comparator
best supportive care
Economic model
BIA only
ICER note
This is a Category 3 submission requesting revision of utilisation estimates and risk-sharing arrangement caps for an already-listed medicine. No new economic evaluation or ICER was presented.
Risk sharing
Risk-sharing arrangement in place — Risk Sharing Arrangement (RSA) with expenditure caps. The sponsor requested either an increase to the existing RSA caps to reflect higher-than-estimated utilisation or a reduction in the rebate percentage payable above the caps. The PBAC did not advise making amendments to the current RSA.
Submission history
Jul 2018: Recommended with restriction · Restricted
Mar 2021: Recommended with restriction · Authority Required